Fluvastatin Sodium Suppliers & Bulk Manufacturers
Available Forms: Tablets / Capsules
Available Strengths: 20 mg, 40 mg, 80 mg
Reference Brands: Lescol (USA), Canef (EU), Vastin (EU)
Category:
Heart Disorder
FLUVASTATIN SODIUM is available in Tablets / Capsules
and strengths such as 20 mg, 40 mg, 80 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, FLUVASTATIN SODIUM is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
FLUVASTATIN SODIUM can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Fluvastatin sodium is the sodium salt of a synthetic lipid-lowering agent that also exhibits potential antineoplastic activity. As a selective HMG-CoA reductase inhibitor, it competitively inhibits the hepatic enzyme responsible for converting HMG-CoA to mevalonate, a key step in cholesterol biosynthesis. This action leads to reduced plasma cholesterol and lipoprotein levels, contributing to cardiovascular risk reduction in patients with hypercholesterolemia or mixed dyslipidemia.
Beyond its lipid-lowering effects, fluvastatin modulates immune responses by suppressing major histocompatibility complex II (MHC II) expression on interferon gamma-stimulated antigen-presenting cells, such as vascular endothelial cells. Additionally, by inhibiting mevalonate-derived intermediates like dolichol, geranylpyrophosphate (GPP), and farnesylpyrophosphate (FPP), fluvastatin interferes with the isoprenylation of intracellular G-proteins such as Ras and Rho. This mechanism can induce antiangiogenic, pro-apoptotic, and antimetastatic effects in susceptible tumor cells, highlighting its potential in adjunctive cancer therapy.
Fluvastatin is administered orally as immediate or extended-release tablets under medical supervision, providing dual benefits in cardiovascular protection and potential anticancer activity. Its well-established safety profile and pharmacological versatility make it a valuable therapeutic agent in both cardiology and investigational oncology settings.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing